Eisai, Biogen apply for Alzheimer's drug approval in Japan

Japanese pharmaceutical firm Eisai Co. said Monday it and U.S. firm Biogen Inc. applied with the health ministry for approval of an Alzheimer's drug that could become the first available in Japan that both treats the disease's cause and slows symptom progression.The two companies hope to gain approval by the end of the year following the U.S. Food and Drug Administration's decision earlier in the month to grant it fast-track approval.Eisai said it had applied with the European Medicines Agency on Jan. 9 for approval to sell the medicine in Europe. The firm also submitted the drug data to Ch…READ FULL ARTICLE